BARDA exercises additional contract options with Aeolus worth $6 million

Aeolus Pharmaceuticals, Inc., announced on Tuesday that the Biomedical Advanced Research and Development Authority has exercised $6 million in additional contract options for the research and development of AEOL-10150.

The compound AEOL-10150 is used as a treatment for the pulmonary syndrome of Acute Radiation Syndrome and delayed effects of acute radiation exposure. Aeolus is developing AEOL-10150 under a five year contract with BARDA, which is worth up to $118 million.

"BARDA's exercise of additional options reflects the significant progress our team has made during the first two years of the Lung-ARS development contract," John L. McManus, the chief executive officer and president of Aeolus, said. "During this period, we delivered valuable animal models for Lung-ARS and made important progress in the manufacturing of AEOL-10150."

The contract was originally awarded on February 11, 2011 to produce the data necessary for an approval under the FDA "Animal Rule" and for a pre-Emergency Use Authorization filing. Should the filing be approved, it would allow the federal government to buy AEOL-10150 for the Strategic National Stockpile.

"The options that BARDA exercised will fund our IND filing for AEOL-10150 as a treatment for Lung-ARS, additional animal efficacy studies designed to optimize timing and duration of dosing and the continued development of large-scale GMP manufacturing capability to meet potential future demand," McManus said. "When combined with our ongoing studies in non-human primates and our completed work in GMP manufacturing development, these options will help Aeolus meet the requirements for a pre-EUA filing for AEOL-10150. We remain grateful to BARDA for the financial support and program input that we receive."

Organizations in this story

Aeolus Pharmaceuticals 26361 Crown Valley Pkwy Mission Viejo, CA 92691

Get notified the next time we write about Aeolus Pharmaceuticals!